Centessa Pharmaceuticals PLC reported Q3 2025 results marked by escalating R&D investment and continued financing pressure, though liquidity remains sufficient through mid-2027.
Financial Performance & Liquidity The nine-month net loss widened to \(\\)(131.4M)\( (up from \)$(124.4M)\(), pushing the Accumulated Deficit to \)$(1.12B)\(. Cash, equivalents, and investments total \)$349.0M\(, providing an estimated runway into mid-2027. Cash flow deteriorated significantly, showing a net cash decrease of \)$332.4M\( for the period, reflecting dramatically reduced financing inflows (\)$8.1M\( vs. \)$36
...